Form D · Biotechnology
EIP Pharma, Inc.
Boston, MA · CIK 0001736525
Offering snapshot reported Jul 20, 2023 · SEC filing
- Reported sold
- $810K Offering amount: $810K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 10, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 20, 2023 | Initial | $810,000 | No comparison | 2 | SEC filing |
| Dec 23, 2021 | Initial | $6,000,000 | No comparison | 3 | SEC filing |
| Jan 15, 2021 | Initial | $5,078,500 | No comparison | 28 | SEC filing |
| Jan 23, 2020 | Initial | $2,730,000 | No comparison | 6 | SEC filing |
| Dec 19, 2018 | Initial | $9,000,000 | No comparison | 4 | SEC filing |
| Apr 13, 2018 | Initial | $20,499,999 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-487497
Source: Form D, filed Jul 20, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Alam | Director, Executive |
| Kelly Blackburn | Executive |
| Noel Donnelly | Executive |
| Sylvie Gregoire | Director |
| Tatjana May | Director |
| Jeff Poulton | Director |
| Marwan Sabbagh | Director |
| William Turner | Executive |
| Frank Zavrl | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 Park Plaza, Suite 424
Boston, MA, 02116
Boston, MA, 02116